Hypolipidemic effects of clofibrate and selected chroman analogs in fasted rats: I. Chow-fed animals.
The hypolipidemic properties of ethyl 6-chlorochroman-2-carboxylate (II), ethyl 6-phenylchroman-2-carboxylate (III) and ethyl 6-cyclohexylchroman-2-carboxylate (IV) were compared to clofibrate (I) in fasted normolipidemic rats. The chroman analog II, like its parent compound, clofibrate, reduced serum and alpha-lipoprotein cholesterol concentrations. Although analog III had no effect on serum cholesterol, it caused a slight elevation of alpha-lipoprotein cholesterol concentration. Serum free cholesterol was increased and LCAT activity was reduced in clofibrate-treated rats. The hypolipidemic agents had no consistent effect on liver lipid concentrations and liver microsomal HMG-CoA reductase activity. In addition, we have shown that drug efficacies varied directly with seasonal variations in serum lipid concentrations.
D000818:Animals; D001578:Benzopyrans / Q000494:pharmacology*; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL; D002839:Chromans / Q000494:pharmacology*; D002994:Clofibrate / Q000031:analogs & derivatives* / Q000494:pharmacology; D005215:Fasting; D008055:Lipids / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D008297:Male; D007862:Phosphatidylcholine-Sterol O-Acyltransferase / Q000097:blood; D051381:Rats; D011919:Rats, Inbred Strains; D012621:Seasons; D014280:Triglycerides / Q000097:blood
D001578:Benzopyrans; D008076:Cholesterol, HDL; D002839:Chromans; D008055:Lipids; D008075:Lipoproteins, HDL; D014280:Triglycerides; D002784:Cholesterol; D007862:Phosphatidylcholine-Sterol O-Acyltransferase; D002994:Clofibrate